Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J/Merck says Pepcid AC onset of action is comparable to Tagamet HB in Sept. 5 suit.

This article was originally published in The Tan Sheet

Executive Summary

PEPCID AC ONSET OF ACTION COMPARABLE TO TAGAMET HB, J&J/MERCK ARGUES in a complaint filed Sept. 5 in District Court for the Southern District of New York. Based on "several" head-to-head comparisons between the two H2 antagonists, Johnson & Johnson/Merck maintained that "Pepcid AC and Tagamet HB have repeatedly been shown to work at the same rate of speed." J&J/Merck said it has conducted comparative assessments of the products in both acid control and symptom relief.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS084275

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel